Kodiak Sciences Inc. (NASDAQ: KOD) had its price target lowered by analysts at JPMorgan Chase & Co. from $12.00 to $10.00. They now have a "neutral" rating on the stock.
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformPR Newswire
- Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 3/28/24 - Miss
KOD
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- KOD's page on the SEC website